Molecular sensor enables electromagnetic remote control of gene therapy in mice

A team at Dongguk University in South Korea has developed a gene switch that can be turned on and off remotely using low-frequency electromagnetic fields (EMF). The work, published in Cell, addresses longstanding limitations of existing gene-control methods, which often rely on drugs with side effects or stimuli such as light that cannot penetrate deep tissue.

The researchers exposed mouse brain tissue to a 2.0 millitesla, 60 hertz EMF and used single-cell RNA sequencing to identify genes that responded. Only the Lgr4 gene showed exclusive upregulation. Its promoter was then engineered into an EMF-inducible (Ei) switch that drives expression of a linked gene.

In transgenic mice carrying a green fluorescent protein reporter under the Ei switch, whole-body EMF exposure produced strong fluorescence throughout the body, while targeted exposure activated expression only in specific organs. When the field was turned off, gene activity returned to baseline within 24 hours, demonstrating precise, reversible, and spatiotemporal control.

A genome-wide CRISPR-Cas9 knockout screen identified cytochrome b5 type B (Cyb5b), a membrane-associated protein, as the molecular sensor mediating the response. The study reports that Cyb5b generates rhythmic calcium influx oscillations in response to EMF, providing a specific activation code for the target gene. The authors state this may be the first reported molecular sensor for electromagnetic fields.

The team demonstrated several therapeutic proofs of concept. In an Alzheimer's disease mouse model, the system decoupled brain aging from amyloid β plaque deposition. Cyclic EMF exposure achieved partial cellular reprogramming in aged and progeroid mice, improving multiple aging-associated markers. Controlling the Tph2 gene restored serotonin levels and reduced depression-like behaviors in mice. No detectable adverse effects were observed in the study.

The researchers suggest the technology could shift gene therapy from a single irreversible dose toward real-time, adjustable treatments administered via wearable devices or clinical equipment. They emphasize that further validation and testing are required before clinical application.